Roxadustat: Phase III started

AstraZeneca disclosed in its 2Q14 financial results that it began an open-label, international Phase III trial to compare thrice-weekly oral roxadustat vs. IV Epogen epoetin alfa for >=52 weeks in about 750 patients with ESRD who are on dialysis. Roxadustat is also being evaluated in the Phase III ALPS trial in chronic kidney disease (CKD) patients who are not on dialysis. ...